How ADHD medications work in adults

ADHD medications are often explained with a one-line story about dopamine. The FDA labels are more careful than that, and the careful version is more useful when you are deciding whether medication is worth trying. This article covers what the labels say about how each class acts in the brain, how the newer prodrug designs differ, and what the research says about how much difference medication makes for adults. It is general education, not advice about any particular medication. Starting, stopping or changing a medication is a decision to make with your prescriber.

What the FDA labels actually say

Every prescription drug label has a section called Mechanism of Action. For ADHD medications, these sections share a striking sentence: the way the drug improves ADHD is not known.

• Amphetamines (for example, Adderall XR and Vyvanse): the labels describe them as "non-catecholamine sympathomimetic amines with CNS stimulant activity" and add that the mode of therapeutic action in ADHD is not known. Under pharmacodynamics, they state that amphetamines "block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines."
• Methylphenidate (for example, Concerta): the label says the mode of therapeutic action is not known and that methylphenidate blocks the reuptake of norepinephrine and dopamine and increases their release.
• Atomoxetine (Strattera): the precise mechanism is unknown, "but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter."
• Viloxazine (Qelbree): the mechanism is unclear, but it is thought to work by inhibiting the reuptake of norepinephrine.
• Guanfacine extended-release (Intuniv): the label calls it a central alpha-2A adrenergic receptor agonist. It acts on a receptor rather than on reuptake.

Dopamine and norepinephrine are chemical messengers that nerve cells release to signal one another. "Blocking reuptake" means the messenger stays in the gap between nerve cells longer instead of being pulled back in. That is a description of what the drug does chemically. It does not prove that ADHD is caused by a shortage of either messenger, and the labels do not claim that.

Stimulants and nonstimulants at a glance

The practical differences between these groups (how fast they act, who they suit and how they are regulated) are covered in stimulant vs nonstimulant ADHD medication. The legal side, including why stimulants cannot be refilled, is in ADHD medication schedules and controlled substances.

Prodrugs: medicines that switch on inside the body

Two products are designed as prodrugs, meaning the swallowed molecule is inactive and the body converts it into the active drug.

• Lisdexamfetamine (Vyvanse and generics) is a prodrug of dextroamphetamine. The label says it is converted to dextroamphetamine and the amino acid l-lysine "primarily in blood due to the hydrolytic activity of red blood cells." It also notes that lisdexamfetamine itself does not bind to the sites responsible for reuptake of norepinephrine and dopamine.
• Serdexmethylphenidate, one of the two ingredients in Azstarys, is a prodrug of dexmethylphenidate. Its label says it is likely converted mainly in the lower gastrointestinal tract. The capsule also contains ready-acting dexmethylphenidate.

Prodrug design changes how the drug is released over the day. The active ingredient that reaches the brain is still a stimulant, and both products carry the stimulant boxed warning. Release designs are explained in extended-release ADHD medications explained.

How much difference medication makes for adults

Researchers summarize trial results with a standardized mean difference (SMD). It compares the average symptom change on medication with the average change on placebo, scaled so that different rating scales can be pooled. A more negative number means a larger average reduction in symptoms than placebo.

The largest comparison of ADHD medications, a 2018 network meta-analysis in Lancet Psychiatry by Cortese and colleagues, pooled 133 double-blind trials, 51 of them in adults. On clinician ratings at about 12 weeks, the adult results were:

The authors concluded that, taking efficacy and tolerability together, the evidence supports amphetamines in adults as a preferred first choice for short-term treatment. They also found more people stopped amphetamines, methylphenidate and atomoxetine because of side effects than stopped placebo, and that there was too little data at 26 and 52 weeks to draw conclusions.

A 2025 component network meta-analysis by Ostinelli and colleagues, covering 113 trials and 14,887 adults, reached a similar short-term picture. Stimulants and atomoxetine were the only treatments that reduced core symptoms on both self-rated and clinician-rated scales. The authors added two cautions: ADHD medications were not efficacious on other outcomes such as quality of life, and evidence over the longer term is underinvestigated. Bupropion is not FDA-approved for ADHD, so any use of it for ADHD is off-label.

A fuller walk through these studies, including the large registry studies on longer-term outcomes, is in does ADHD treatment work in adults?

Averages are not predictions

An average effect hides a wide spread. England's NICE guideline (NG87), one of the main guidelines that addresses adults, tells prescribers to be aware that "effect size, duration of effect and adverse effects vary from person to person." It also asks clinicians to correct misconceptions, for example by telling people that medication does not change personality. Some adults notice a clear change, some notice little, and some stop because of side effects. That variation is why the first weeks on a medication are usually a period of close follow-up rather than a fixed plan, as described in starting ADHD medication: the first three months.

Safety warnings that follow from how they work

• Stimulants: in May 2023 the FDA required a boxed warning across the class on abuse, misuse and addiction. The Adderall XR label, for example, tells prescribers to assess each patient's risk before prescribing and to reassess it throughout treatment. Stimulant labels also warn about increases in blood pressure and heart rate; see ADHD medication, heart health and blood pressure.
• Atomoxetine and viloxazine: both carry boxed warnings about suicidal thoughts and behaviors. Strattera's warning is worded for pediatric patients, while Qelbree's says higher rates were reported in patients treated with Qelbree than with placebo.
• Monoamine oxidase inhibitors (MAOIs): stimulant, atomoxetine and viloxazine labels list use with an MAOI, or within 14 days of stopping one, as a contraindication.

Questions to ask your prescriber

• Which group does this medication belong to, and why is it the one you suggest for me?
• What change should I expect to notice, and how will we measure it?
• Which side effects are common, and which ones mean I should call you?
• Does anything I already take, including an antidepressant, interact with it?
• Is it a controlled substance, and how will refills and follow-up work where I live?

Rules for controlled-substance prescriptions differ between the two states: see New York's rules for ADHD stimulant prescriptions and New Jersey's rules. Dr. Shershow is a psychiatrist licensed in New York and New Jersey who evaluates adults for ADHD and provides medication management when medication is appropriate. The adult ADHD treatment page explains how that care works.